Curated News
By: NewsRamp Editorial Staff
September 12, 2024
Clene to Present at H.C. Wainwright 26th Annual Global Investment Conference
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Clene (NASDAQ: CLNN) will present at the H.C. Wainwright 26th Annual Global Investment Conference, offering potential investment opportunities.
- The conference will feature a virtual presentation and one-on-one investor meetings discussing Clene's lead drug candidate CNM-Au8 and its potential FDA approval for ALS treatment.
- CNM-Au8 has shown promise in restoring and protecting neurological function, bringing hope to patients with neurodegenerative conditions like ALS and MS.
- Clene's participation in the conference and the potential new drug application for CNM-Au8 offer an interesting opportunity for investors and anyone interested in neurodegenerative disease treatments.
Impact - Why it Matters
This news showcases Clene's latest achievements and updates, providing hope for patients with neurodegenerative conditions. The company's research and drug development efforts could potentially lead to new treatment options for conditions like ALS and MS, impacting the lives of many individuals.
Summary
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including ALS and MS, will present at the H.C. Wainwright 26th Annual Global Investment Conference. Lead drug candidate CNM-Au8 has shown promise in restoring and protecting neurological function, offering hope for patients with neurodegenerative conditions. The company is seeking FDA approval to file a new drug application for CNM-Au8, using the accelerated approval pathway for treatment of ALS.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene to Present at H.C. Wainwright 26th Annual Global Investment Conference
